Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Free Cash Flow (2016 - 2025)

Cytosorbents' Free Cash Flow history spans 15 years, with the latest figure at -$4.9 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$4.9 million for Q4 2025, down 131.16% from a year ago — trailing twelve months through Dec 2025 was -$12.5 million (up 13.13% YoY), and the annual figure for FY2025 was -$12.5 million, up 13.13%.
  • Free Cash Flow for Q4 2025 was -$4.9 million at Cytosorbents, down from -$2.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.5 million in Q2 2025 to a low of -$9.1 million in Q4 2021.
  • The 5-year median for Free Cash Flow is -$4.8 million (2024), against an average of -$4.8 million.
  • The sharpest move saw Free Cash Flow plummeted 648.71% in 2021, then skyrocketed 67.85% in 2025.
  • Year by year, Free Cash Flow stood at -$9.1 million in 2021, then soared by 40.66% to -$5.4 million in 2022, then dropped by 19.99% to -$6.5 million in 2023, then surged by 67.18% to -$2.1 million in 2024, then plummeted by 131.16% to -$4.9 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$4.9 million, -$2.6 million, and -$1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.